• Brii Biosciences filed a demand for arbitration on April 16, 2026 against Vir Biotechnology at Judicial Arbitration and Mediation Services over alleged breaches of a 2018 collaboration agreement covering the elebsiran hepatitis B program.
• The dispute also covers a Dec. 19, 2024 letter agreement that shifted drug product formulation manufacturing responsibility from Vir to Brii.
• The case remains at an early stage with no mutual resolution, leaving the future of elebsiran uncertain.
• The company cannot commit to a Phase 3 trial of an elebsiran-containing combination therapy until the arbitration claims are resolved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260522-12168587), on May 22, 2026, and is solely responsible for the information contained therein.